奥他凡星：全球首次批准。
Oritavancin: first global approval.
机构信息
Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand,
出版信息
Drugs. 2014 Oct;74(15):1823-8. doi: 10.1007/s40265-014-0295-4.
Oritavancin (Orbactiv(®)) is a lipoglycopeptide antibacterial drug with activity against Gram-positive bacteria developed by The Medicines Company as a single-dose treatment for acute bacterial skin and skin structure infections (ABSSSI). The drug received its first global approval for this indication in the US in August 2014, and is under regulatory review in the EU. This article summarises the milestones in the development of oritavancin leading to this first approval for the treatment of ABSSSIs caused by Gram-positive bacteria.
奥利万星（奥他凡星(®)）是一种糖肽类抗生素药物，对革兰氏阳性菌具有活性，由 The Medicines Company 开发，作为治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）的单剂量疗法。该药于 2014 年 8 月在美国首次获得该适应证的全球批准，并正在欧盟接受监管审查。本文总结了奥利万星研发过程中的重要里程碑，这些里程碑使该药首次获批用于治疗革兰氏阳性菌引起的 ABSSSIs。
Zotero 插件